New allergy pill shows promise for kids in Long-Term trial
NCT ID NCT01900054
First seen Jan 10, 2026 · Last updated Jun 20, 2026 · Updated 24 times
Summary
This study tested the long-term safety and effectiveness of TAU-284 (bepotastine besilate) in 58 children aged 7 to 15 with perennial allergic rhinitis (year-round nasal allergies). Over 12 weeks, researchers tracked side effects and changes in sneezing, runny nose, and congestion. The goal was to see if the drug is safe and helpful for long-term use in kids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERENNIAL ALLERGIC RHINITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Reserch site
Kanagawa, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bepotastine besilate (antihistamine tablet)
What this could lead to
If successful, this could confirm a safe and effective long-term allergy medication option for children with year-round nasal allergies.
What could go wrong
This is a small, completed phase 3 trial with only 58 participants, so results may not apply to all children. As with any drug, side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.